Evidence map›Paper›PMID 35142110›Full record

ArticleCancer medicine2022

Authors' response: Comment on "clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma".

Di Lu, Jianjun Yang, Xiguang Liu, Siyang Feng, Xiaoying Dong, Xiaoshun Shi, Jianxue Zhai, Shijie Mai, Jianjun Jiang, Zhizhi Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Di LuDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jianjun YangDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiguang LiuDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Siyang FengDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaoying DongDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaoshun ShiDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID 0000-0003-3467-6386
Jianxue ZhaiDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Shijie MaiDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jianjun JiangDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhizhi WangDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hua WuDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Kaican CaiDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID 0000-0003-4664-6694

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenocarcinoma of LungAdenocarcinoma, PapillaryLung NeoplasmsHumansNeoplasm StagingPrognosisRetrospective Studies

Identifiers

PMID35142110
PMCPMC9089219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.